Aminopyridazine derivatives and TXA2-PGI2 balance.
Experiments carried out under the conditions adopted showed the strong affinity of aminopyridazine derivatives for the eicosanoids TXA2 and PGI2. But this affinity depended on the chemical structure of the molecule: a small change in the radical grafted onto the pyridazine ring could completely modify the pharmacological activity of the molecule. Consequently it should be possible to control the properties of pyridazine derivatives according to pharmacological needs. Thus: --pyridazin-3-one derivatives were mainly active on TXA2 biosynthesis: 2-aminoalkyl 5-arylidene 6-methyl (4H) pyridazin-3-ones inhibited the TXA2-synthesizing activity of cardiac tissue whereas 3-amino 4,6-diaryl pyridazin-3-ones were specific inhibitors of the TXA2 synthetase in vitro, but these effects were weak. --pyridazine derivatives were devoid of any effect on the TXA2-synthesizing activity of cardiac tissue: they acted on either TXA2 synthetase or PGI2 synthetase according to the radicals grafted onto the pyridazine ring. --none of the compounds under study was active on the PGI2-synthesizing activity of cardiac tissue.
Chanh
P H
PH
Pharmacologie de la Régulation C.N.R.S., Institut de Physiologie, Toulouse, France.
Lasserre
B
B
Kaiser
R
R
Couquelet
J
J
Coudert
P
P
Rubat
C
C
D000818:Animals; D011464:Epoprostenol / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011724:Pyridazines / Q000378:metabolism*; D011817:Rabbits; D013928:Thromboxane A2 / Q000378:metabolism*
D011724:Pyridazines; D013928:Thromboxane A2; D011464:Epoprostenol